Anti-TNFR2 antibodies and uses thereof
Anti-TNFR2 antibodies with specific CDR sequences address the need for improved cancer therapies by inhibiting TNFR2 signaling, enhancing immune responses, and effectively treating cancers like colorectal, ovarian, and glioma.
Patent Information
- Application Number
- JP2024538148
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-22
- Filing Date
- 2022-12-22
- Publication Date
- 2024-12-26
AI Technical Summary
Current cancer therapies, particularly those involving antibodies, lack effective targets for modulating the immune response to combat cancer and autoimmune diseases, with TNFR2 offering a promising but underexplored receptor for therapeutic intervention.
Development of anti-TNFR2 antibodies and antigen-binding fragments with specific CDR sequences that can inhibit TNFR2 signaling, enhancing immune responses and potentially treating various cancers by blocking the receptor's pathway.
The anti-TNFR2 antibodies enhance immune responses, inhibit tumor growth, and provide therapeutic options for cancers such as colorectal, ovarian, and glioma by promoting CD8+ T cell proliferation and cytokine release, while being safe and effective with minimal side effects.
Smart Images
Figure 2024547122000001_ABST
Abstract
Citation Information
Patent Citations
Anti-TNFR2 antibody and use thereof
EP3907240A1
Composition and methods for Anti-TNFR2 antibodies
US20190202925A1
Antagonistic Anti-tumor necrosis factor receptor superfamily polypeptides
US20210340268A1
Anti-TNFR2 antibodies and uses thereof
US20210371537A1
Antagonistic Anti-tumor necrosis factor receptor superfamily polypeptides
WO2019094559A2